Active Ingredient History

  • Now
Sprifermin (INN), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18) which is under development by Merck and Nordic Bioscience for the treatment of osteoarthritis. As a recombinant form of FGF18, sprifermin is a potent agonist of the FGFR2 and FGFR3.   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
as902330 | fgf-18 | fgf-18 protein, human | fgf18 protein, human | fgf-18 protein, mouse | fgf18 protein, mouse | fgf-18 protein, rat | fgf18 protein, rat | fibroblast growth factor 18 | fibroblast growth factor 18, human | fibroblast growth factor 18, mouse | fibroblast growth factor 18, rat | sprifermin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue